Truveta is a healthcare data platform collaboration with physicians, life science researchers, and others in the healthc
Truveta is a healthcare data platform collaboration with physicians, life science researchers, and others in the healthcare community.
Enterprise Systems (Healthcare)📍 Bellevue, WAFounded 2020
Current Valuation
$1.0B
as of 2025-Q1
UNICORN
QL Price
$1.0B
0% vs last round
QuantLogix's current estimate for Truveta, published 2026-09-07 — in line with the last disclosed round of $1.0B (2025-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.0B
2025-Q1
weight 0.37
How this price has held up
No round has priced for Truveta since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Truveta, 2026-09-07 (3c85c9c886878234).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Truveta going public?
No. Truveta is private and has not filed to go public. There is no S-1 on file.
What is Truveta's valuation in 2026?
Truveta is valued at $1.0B as of 2025-Q1, set by its Series C ($320M, Jan 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Truveta filed an S-1?
No public S-1 is on file for Truveta.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2020
HQ
Bellevue, WA
Employees
413
Total Raised
$515M
Last Round
Series C — $320M (Jan 2025)
IPO Status
private
Fundraising Status
Series C · $320M · 1y 8mo ago
privateTotal raised $515M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$320M
Jan 2025
—
$1.0B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Truveta — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-03. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
15% of roles posted in last 30d
Open roles
40
via greenhouse
Product-build share
83%
engineering, research, product, design
Trajectory
steady
heavy product build — 83% of open roles are product-building functions (engineering/research/product) — 15 of 40 open roles are engineering.
Counted from Truveta's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyHealth CareWellness
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q1. Refreshed quarterly.